Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Label-free proteomic profiling of Alzheimer' s disease mice model hippocampus at the age of 8 months

ABSTRACT: Alzheimer’s disease (AD) is the most common form of dementia with high morbidity in the elderly and the hippocampus is one of the key structures severely affected in AD. We performed hippocampal proteomic analysis of 8-month old App-NLF mice model of AD using a liquid-chromatography/mass-spectrometry system to investigate the proteins that are differentially expressed in order to identify changes in the proteins and molecular pathways that might promote the disease.

ORGANISM(S): Mus Musculus (mouse)

SUBMITTER: Yoshio Goshima

PROVIDER: PXD012541 | JPOST Repository | Wed Feb 05 00:00:00 GMT 2020

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	170317Elite_Aderemi_KI_1.raw	Raw
	170317Elite_Aderemi_KI_2.raw	Raw
	170317Elite_Aderemi_KI_3.raw	Raw
	170317Elite_Aderemi_KI_5.raw	Raw
	170317Elite_Aderemi_WT_10.raw	Raw

Items per page:

1 - 5 of 15

Similar Datasets

Phospho-proteomic profiling of Alzheimer' s disease mice model hippocampus at the age of 8 months

Project description:Alzheimer’s disease (AD) is the most common form of dementia with high morbidity in the elderly and the hippocampus is one of the key structures that undergo severe atrophy in AD. We performed hippocampal phospho-proteomic profiling of the App-NLF mice model of AD at the age of 8 months using a liquid-chromatography/mass-spectrometry system to investigate the upregulated and downregulated phosphosites might contribute to the pathogenesis of AD.

2020-01-29 | PXD012543 | JPOST Repository

Mouse hippocampus LC/MS with TMT labeling

Project description:Transgenic mouse models have been widely used to investigate the pathology of Alzheimer’s disease (AD). To elucidate underlying mechanisms of AD pathogenesis by amyloid beta (Aβ) and tau, we have generated a novel animal model of AD; ADLP - APT mice (Alzheimer’s Disease-Like Pathology) – carrying mutations of human amyloid precursor protein (APP), human presenilin-1 (PS1) and human tau. We profiled 9,824 proteins in the hippocampus of ADLP model mice using quantitative proteomics. To identify functional signatures in pathology of ADLP - APT mice, in-depth bioinformatics analysis was performed. For a longitudinal change of differentially expressed proteins (DEPs), we identified ADLP - APT mice hippocampal proteome in an age-dependent manner. Network maps of interactome between Aβ and tau in newly generated ADLP - APT mice reveal relationship between accelerated NFT pathology of AD and proteomic changes.

2018-01-25 | PXD006214 | Pride

Hydroxyurea protects hippocampal neurons against oxidative, metabolic and excitotoxic stress, and improves spatial memory in a mouse model of Alzheimer’s disease (Rat)

Project description:Alzheimer’s disease (AD) is an age-related neurodegenerative disorder characterized by accumulation of amyloid β-peptide (Aβ) plaques in the brain and decreased cognitive function leading to dementia. We determined if hydroxyurea (HU), a ribonucleotide reductase inhibitor known to activate adaptive cellular stress responses in fibroblasts, could protect rat hippocampal neurons against oxidative-, excitatory-, mitochondrial-, and Aβ-induced stress and if HU treatment could improve learning and memory in a mouse model of AD (APP/PS1 double mutant transgenic mice). HU treatment attenuated the loss of cell viability induced by treatment of hippocampal neurons with hydrogen peroxide, glutamate, rotenone, and Aβ1-42. HU treatment also attenuated reductions of mitochondrial reserve capacity, maximal respiration, and cellular ATP content induced by hydrogen peroxide treatment. In vivo, treatment of APP/PS1 AD mice with HU (45 mg/kg/day) improved spatial memory performance in the hippocampus-dependent Morris water maze task. In summary, HU provides neuroprotection against toxic insults, improves mitochondrial bioenergetics, and improves spatial memory in a mouse model of AD. HU may offer a new therapeutic approach to delay cognitive decline in AD.

2018-09-10 | GSE111941 | GEO

Hydroxyurea protects hippocampal neurons against oxidative, metabolic and excitotoxic stress, and improves spatial memory in a mouse model of Alzheimer’s disease (Mouse)

2018-09-10 | GSE111940 | GEO

Whole-transcriptomic analysis of circRNA-miRNA-mRNA ceRNA network in 4-month APP/PS1 mouse hippocampus

Project description:Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, and the molecular mechanisms of AD remain unclear. Accumulating evidence indicates the involvement of non-coding RNAs in AD pathogenesis. Here, we applied RNA-seq to explore the expression changes of circRNA, miRNA, and mRNA simultaneously, and investigate competing endogenous RNA (ceRNA) networks in hippocampus of 4-month APP/PS1 and wild-type mice.

2022-07-27 | GSE166393 | GEO

Mouse Wild Type and APP transgenic (Tg2576) hippocampus and response to LXR Agonist

Project description:The amyloidogenic processing of APP to A-beta is known to play a central role in Alzheimer’s disease pathogenesis. Despite this, however, the physiological role of APP and its processing still remains elusive. In the current study we utilzed a transcriptional profiling approach, to determine the pathways that may become dysregulated in the brains of APPswe transgenic mice (Tg2576). As many pathways linked to Alzheimer’s disease are also linked to cholesterol metabolism, we also treated the Tg2576 mice with LXR agonist TO901317, to determine the effects of LXR agonists on the hippocampal transcriptome of Tg2576 mice. We used microarrays to identify gene expression modulated in hippocampus of transgenic TG2576 mice that express human APP containing the Swedish mutation and the transcriptional responses to treatment with an LXR agonist.

2017-08-01 | GSE31624 | GEO

Early amyloid-induced changes in microglia gene expression in APP/PS1 mice [scRNA-seq]

Project description:Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the most common cause of dementia, characterized by deposition of extracellular amyloid-beta (Aβ) aggregates and intraneuronal hyperphosphorylated Tau. Many AD risk genes, identified in genome-wide association studies (GWAS), are expressed in microglia, the innate immune cells of the central nervous system. Specific subtypes of microglia emerged in relation to AD pathology, such as disease-associated microglia (DAMs), which increased in number with age in amyloid mouse models and in human AD cases. However, the initial transcriptional changes in these microglia in response to amyloid are still unknown. Here, to determine early changes in microglia gene expression, hippocampal microglia from APPswe/PS1dE9 (APP/PS1) mice and wildtype littermates were isolated and analyzed by RNA sequencing (RNA-seq). By bulk RNA-seq, transcriptomic changes were detected in hippocampal microglia from 6-months-old APP/PS1 mice. By performing single cell RNA-seq of CD11c-positive and negative microglia from 6-months-old APP/PS1 mice and analysis of the transcriptional trajectory from homeostatic to CD11c-positive microglia, we identified a set of genes that potentally reflect the initial response of microglia to Aβ.

2024-04-01 | GSE226938 | GEO

Early amyloid-induced changes in microglia gene expression in APP/PS1 mice [bulk RNA-seq]

2024-04-01 | GSE226937 | GEO

APP and its intracellular domain modulate Alzheimer’s disease risk gene networks in transgenic APPsw and PSEN1M146I porcine models [hippocampus]

Project description:Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most frequent cause of dementia. The disease has a substantial genetic component comprising both highly penetrant familial mutations (APP, PSEN1 and PSEN2) and sporadic cases with complex genetic etiology. Mutations in APP and PSEN1/2 alter the proteolytic processing of APP to its metabolites, including Ab and APP Intracellular Domain (AICD). In this study, we use transgenic porcine models carrying the human APPsw and PSEN1M146I transgenes to demonstrate the pathobiological relevance of transcriptional regulation facilitated by APP and its AICD domain. Through molecular characterization of hippocampal tissue, we describe the differential expression of gene sets that cluster in molecular pathways with translational relevance to AD. We further identify phosphorylated and unphosphorylated AICD in differential complexes with proteins implicated in signal transduction and transcriptional regulation. Integrative genomic analysis of transcriptional changes in somatic cell cultures derived from pigs treated with g-secretase inhibitor demonstrates the importance of g-secretase APP processing in transcriptional regulation. Collectively, our data supports a model in which APP, and in particular its AICD domain, modulates gene networks associated with AD pathobiology through interaction with signaling proteins.

2024-02-04 | GSE254548 | GEO

A multi¬omic analysis reveal gender differences in the hippocampus of Alzheimer disease subjects

Project description:Alzheimer’s disease (AD) is the most common neurodegenerative pathology affecting more than 20 million people worldwide and the leading cause of dementia. Although AD neuropathology has been well defined, the underlying causes of the disease remain debatable. Recently, sex and gender are emerging as crucial drivers of development and progression of AD dementia. So, to investigate the molecular basis of gender¬related influences on the pathology of AD, we analyzed hippocampal brain tissues from control (CTR) and Alzheimer’s Disease (AD) patients using an integrated proteomic, metabolomics and transcriptomic approach. A principal component analysis carried out to identify major differences among the two datasets highlights differences among AD and CTR. Focusing on the gender dependent omic changes, comparative analyses were carried out considering males (M) and females (F) as separate subgroups in AD patients and in healthy subjects. The analysis was conducted considering proteins differentially expressed if they were present only in one condition or showed significant t¬test difference. The results strongly suggest that there is a significant difference between male and female in all the omic data sets either in the neurodegenerative disease and in the control. Preliminary results from bioinformatics analysis highlight major differences in energetic metabolism, cytoskeleton organization and oxidative stress response.The results are of main relevance for future clinical interventions that can reduce dementia risk in both male and female patients.

2024-10-01 | PXD034137 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data